COLLABORATIVE ARRANGEMENTS (Tables)

9 Months Ended

Sep. 30, 2013

COLLABORATIVE ARRANGEMENTS

Schedule of revenue recognized from collaborative arrangements

	Three months Ended September 30,				Nine months Ended September 30,
(In thousands)	2013		2012		2013		2012
GSK	$	415	$	1,430	$	3,059	$	4,291
Astellas	—		—		—		125,669
Other	24		—		51		—
Total revenue	$	439	$	1,430	$	3,110	$	129,960

Summary of reductions to R&D expenses related to the reimbursement payments

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2013		2012		2013		2012
GSK	$	181	$	40	$	517	$	116
Merck	1,501		—		4,579		—
Alfa Wassermann	471		—		924		—
R-Pharm	—		—		86		—
Total reduction to R&D expense	$	2,153	$	40	$	6,106	$	116

Schedule of revenue recognized from GSK under the LABA collaboration and strategic alliance agreements

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2013		2012		2013		2012
LABA collaboration	$	—	$	907	$	1,814	$	2,722
Strategic alliance—MABA program license	415		523		1,245		1,569
Total revenue from GSK Collaborations	$	415	$	1,430	$	3,059	$	4,291